President and CEO of Seattle Genetics Inc (30-Year Financial, Insider Trades) Clay B Siegall (insider trades) sold 28,472 shares of SGEN on 10/08/2019 at an average price of $82.47 a share. The total sale was $2.3 million.
Seattle Genetics Inc is a biotechnology company. The company is focused on development and commercialization of targeted therapies for the treatment of cancer. Its products are ADCETRIS (brentuximab vedotin) US and ADCETRIS (brentuximab vedotin) Canada. Seattle Genetics Inc has a market cap of $13.86 billion; its shares were traded at around $81.55 with and P/S ratio of 17.29. GuruFocus has detected 4 severe warning signs with Seattle Genetics Inc. .
CEO Recent Trades:
- President and CEO Clay B Siegall sold 28,472 shares of SGEN stock on 10/08/2019 at the average price of $82.47. The price of the stock has decreased by 1.12% since.
CFO Recent Trades:
- CFO Todd E Simpson sold 15,000 shares of SGEN stock on 09/30/2019 at the average price of $85. The price of the stock has decreased by 4.06% since.
Directors and Officers Recent Trades:
- Director David W Gryska sold 5,000 shares of SGEN stock on 10/01/2019 at the average price of $85.09. The price of the stock has decreased by 4.16% since.
- GC/EVP, Leg Affairs Jean I Liu sold 7,432 shares of SGEN stock on 09/30/2019 at the average price of $86. The price of the stock has decreased by 5.17% since.
- Chief Medical Officer Roger D Dansey sold 3,000 shares of SGEN stock on 09/25/2019 at the average price of $73.8. The price of the stock has increased by 10.5% since.
For the complete insider trading history of SGEN, click here
.
